文献速递主动脉疾病

医生改良支架在择期复杂腹主动脉瘤修复中的欧洲多中心初步经验

Physician-Modified Endografts in Elective Care: A Report From the REgistry of MOdified Treo Endografts in Europe (REMOTE).
PubMed 文献 · J Endovasc Ther · 2026-01-08

结果显示技术成功率96.4%,院内无死亡及重大不良事件,短期随访总死亡率3.6%(1例非主动脉相关),再次干预豁免率92.9%,靶血管通畅率98.8%,提示择期PMEG安全可行。

要点

  • 择期Treo装置PMEG修复复杂腹主动脉瘤技术成功率达96.4%。
  • 短期随访总死亡率3.6%,无院内死亡或重大不良事件。
  • 再次干预豁免率92.9%,原发及继发靶血管通畅率均98.8%。

核心结论

  • 择期使用Treo装置行PMEG修复复杂腹主动脉瘤技术成功率高、临床并发症发生率低,支持该方式在择期场景中的安全性和可行性。

主要发现

  • 68.3%的病例纳入至少3个靶血管,装置改良平均耗时47.4±20.3分钟。
  • 技术成功率为96.4%,唯一技术失败与副肾动脉丢失相关,未发生急性肾损伤或内漏。
  • 短期随访(平均5.9±4.8个月)总死亡率为3.6%(n=1,非主动脉相关),再次干预豁免率为92.9%(n=26)。
  • 25%的患者(n=7)出现瘤囊缩小,其余保持稳定;原发和继发靶血管通畅率均为98.8%(n=81),随访影像发现1例肾动脉支架闭塞。

临床怎么用

  • 在有经验的中心,择期PMEG可作为复杂腹主动脉瘤的一种可行治疗选择,技术成功率高且重大并发症少见。
  • 该路径可能缩短从决策到手术的时间,从而降低等待期间破裂风险和患者焦虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Physician-modified endografts (PMEGs) are widely accepted as a viable option in the urgent management of patients with complex abdominal aortic aneurysms (CAAAs). While PMEGs have emerged as the predominant repair modality for CAAAs in the United States, their acceptance in Europe remains limited-particularly in the context of elective repair. The aim of this study was to present the initial experience with elective cases at pioneering European centers offering this treatment. METHODS: This is a retrospective observational study based on an international multicenter registry (REgistry of MOdified Treo endografts in Europe-REMOTE). Data were collected from 4 European centers on patients who underwent elective PMEG repair using the Treo device for CAAAs between August 2023 and February 2025. Demographic characteristics, clinical status, procedural details and follow-up data were recorded. Primary outcomes included technical success, overall and aortic-related mortality, and adverse events. RESULTS: Twenty-eight patients (20 males; mean age 76.3±6.8 years) underwent elective PMEG repair with the Treo device. Most procedures incorporated at least 3 target vessels (68.3%). The average time required for device modification was 47.4±20.3 minutes. Technical success was achieved in 96.4% of cases. The single technical failure was associated with a lost accessory renal artery, with no acute kidney injury occurred nor endoleak observed. There were no in-hospital deaths or major adverse events. At short-term follow-up (mean 5.9±4.8 months), overall mortality was 3.6% (n=1, non-aortic-related). Freedom from reintervention was 92.9% (n=26). Aneurysm sac shrinkage was observed in 25% of patients (n=7), with the remainder showing stability. Primary and secondary target vessel patency rates were both 98.8% (n=81), with one renal stent occlusion noted on follow-up imaging. CONCLUSION: This multicenter retrospective observational study demonstrated that elective PMEG repair of CAAAs using the Treo device is associated with a high-technical-success rate and a low incidence of clinical complications, supporting the safety and feasibility of this approach in the elective setting.Clinical ImpactREMOTE provides a multicentre European snapshot of elective PMEG-FEVAR on a single abdominal platform (Treo), showing high technical success with major clinical complications being uncommon, supporting feasibility in the elective setting. This could change practice by enabling experienced centres to offer a structured elective PMEG pathway and reduce decision-to-operation time from the 1-4 months often seen with CMD logistics to days (or even hours), thereby lowering interval-rupture risk and patient anxiety. For clinicians, this means a more predictable workflow that can shorten the learning curve and broaden access where CMD availability/cost is limiting.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Csobay-Novák C, Dionisi CP, Szentiványi A, et al. Physician-Modified Endografts in Elective Care: A Report From the REgistry of MOdified Treo Endografts in Europe (REMOTE). J Endovasc Ther. 2026. PMID: 41504532. doi:10.1177/15266028251405754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。